Growth Capitalist (https://growthcapitalist.com/author/moriarty/page/168/)
GenVec, Inc. (GNVC) announced that it has secured up to $10,000,000 in an ATM (At the Market) transaction with Roth Capital Partners. The purchase price is the prevailing market price at the time of the Draw Down Notice. Placement Agent counsel was Lowenstein Sandler and issuer counsel was Hogan Lovells. An agreement was reached on February 11, 2014. via PlacementTracker.
LabStyle Innovations Corporation (DRIO) announced that it has raised $4,186,677 in a Units (Common Stock + Warrants) transaction. The common stock was sold at $1.88 per share, an approximate 10% discount to the market price ($2.10) of DRIO at deal announcement. A series of 1,670,216 60-Month Warrants with an exercise price of $2.35 per share (11.9% premium) was issued to the investors in this transaction. Roth Capital Partners, LLC acted as the exclusive agent on the transaction. The investors include Alpha Capital Anstalt, Empery Asset Management LP, and Sabby Management, LLC.
AtriCure, Inc. (ATRC) announced that it has raised $58,193,231 in a CMPO/Overnight transaction. The common stock was sold at $19.25 per share, an approximate 5% discount to the market price ($20.21) of ATRC at deal announcement. Piper Jaffray acted as Sole Book-Running Manager with Canaccord Genuity, Leerink Swann, Stifel Nicolaus Weisel, and Barrington Research Associates as Co-Managers on the transaction. Underwriter counsel was Goodwin Procter and issuer counsel was Keating, Muething & Klekamp. The transaction is expected to close on February 19, 2014.
OXiGENE Inc. (OXGN) announced that it has raised $12,000,001 in a Public Offering/Follow-On transaction. The common stock was sold at $2.05 per share, an approximate 26% discount to the market price ($2.78) of OXGN at deal announcement. A series of 2,926,830 60-Month Warrants with an exercise price of $2.75 per share (1.11% discount) was issued to the investors in this transaction. H.C. Wainwright acted as Sole Book-Runner on the transaction. Underwriter counsel was Ellenoff Grossman & Schole and issuer counsel was Mintz, Levin, Cohn, Ferris, Glovsky & Popeo.
